Arabi et al. functionalized Doxil with CD44 monoclonal antibody (mAb) and compared its antitumor activity with Doxil.95In vitro results showed that the uptake of CD44-targeting (mAb)-modified Doxi in CD44 mouse colon cancer cells was significantly improved compared with Doxil (Fig. 5). The gene discussed is CD44; the disease is colonic neoplasm.